TNFRSF17 and plasma cell myeloma: Teclistamab (JNJ-64007957) is a DuoBody bsAb that induces T cell-mediated cytotoxicity against BCMA-expressing myeloma cells, independently from the amount of sBCMA, APRIL, or BAFF (Pillarisetti et al., 2020).